AMR Logo.png
Mitral Valve Disease Therapeutics Market to Reach $803.4 Million, Globally, by 2032 at 2.8% CAGR: Allied Market Research
25. Juli 2023 11:09 ET | Allied Market Research
Portland, OR, July 25, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Mitral Valve Disease Therapeutics Market by Drug class (Beta blockers, Diuretics, Anticoagulants,...
AMR Logo.png
Mitral Valve Disease Market Is Expected to Generate $5.7 Billion by 2031: Allied Market Research
24. April 2023 11:24 ET | Allied Market Research
Portland, OR, April 24, 2023 (GLOBE NEWSWIRE) -- According to the report published by allied Market Research, the global mitral valve disease market garnered $2.5 billion in 2021, and is estimated...
Neovasc_Logo-web-header.jpg
Neovasc Announces Notice of US Patent Granted for Tiara™ Transcatheter Device for Treatment of Severe Mitral Regurgitation
15. Oktober 2019 07:00 ET | Neovasc, Inc.
VANCOUVER, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter...